1. Home
  2. LGND vs FUL Comparison

LGND vs FUL Comparison

Compare LGND & FUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGND
  • FUL
  • Stock Information
  • Founded
  • LGND 1987
  • FUL 1887
  • Country
  • LGND United States
  • FUL United States
  • Employees
  • LGND 68
  • FUL N/A
  • Industry
  • LGND Biotechnology: Pharmaceutical Preparations
  • FUL Home Furnishings
  • Sector
  • LGND Health Care
  • FUL Industrials
  • Exchange
  • LGND Nasdaq
  • FUL Nasdaq
  • Market Cap
  • LGND 3.2B
  • FUL 3.2B
  • IPO Year
  • LGND 1992
  • FUL N/A
  • Fundamental
  • Price
  • LGND $184.49
  • FUL $60.44
  • Analyst Decision
  • LGND Strong Buy
  • FUL Buy
  • Analyst Count
  • LGND 8
  • FUL 5
  • Target Price
  • LGND $144.71
  • FUL $68.60
  • AVG Volume (30 Days)
  • LGND 139.7K
  • FUL 499.8K
  • Earning Date
  • LGND 08-05-2025
  • FUL 09-24-2025
  • Dividend Yield
  • LGND N/A
  • FUL 1.56%
  • EPS Growth
  • LGND N/A
  • FUL N/A
  • EPS
  • LGND N/A
  • FUL 2.07
  • Revenue
  • LGND $181,488,000.00
  • FUL $3,502,085,000.00
  • Revenue This Year
  • LGND $18.41
  • FUL N/A
  • Revenue Next Year
  • LGND $18.87
  • FUL $3.27
  • P/E Ratio
  • LGND N/A
  • FUL $29.09
  • Revenue Growth
  • LGND 53.40
  • FUL N/A
  • 52 Week Low
  • LGND $81.74
  • FUL $47.56
  • 52 Week High
  • LGND $129.90
  • FUL $81.03
  • Technical
  • Relative Strength Index (RSI)
  • LGND 79.42
  • FUL 45.65
  • Support Level
  • LGND $179.40
  • FUL $57.82
  • Resistance Level
  • LGND $184.26
  • FUL $59.97
  • Average True Range (ATR)
  • LGND 4.60
  • FUL 1.36
  • MACD
  • LGND 0.44
  • FUL -0.13
  • Stochastic Oscillator
  • LGND 100.00
  • FUL 39.96

About LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

About FUL H. B. Fuller Company

H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. It generates the maximum revenue from hygiene, health and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based and solvent-based products for applications in various markets, including packaging , converting, nonwoven and hygiene (disposable diapers, feminine care and medical garments) and health and beauty. The company generates around half of its revenue in the United States.

Share on Social Networks: